Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk’s (NVO) etavopivat was granted FDA orphan designation for treatment of thalassemias, according to a post on the agency’s ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its ...